Post Exposure Prophylaxis News and Research

RSS

Bioethics Commission makes recommendations on preparedness for public health emergencies

Today the Presidential Commission for the Study of Bioethical Issues (Bioethics Commission) reported that the federal government has both a prudential and a moral responsibility to actively participate in coordinated global responses to public health emergencies wherever they arise.

28 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.

21 Jul 2014

Emergent BioSolutions reports total revenue of $53.9 million for Q1 2014

Emergent BioSolutions Inc. reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or $0.55 per share, as compared to a net loss of $8.1 million, or $0.22 per share, in 2013.

9 May 2014

FDA grants Orphan Drug Designation to Emergent BioSolutions' BioThrax for PEP of anthrax disease

Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis.

21 Apr 2014

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

Researchers conduct a memory study, scan a participant's brain, and find more than they bargain for: a tumor. What do the researchers owe the participant? What does the participant want to know?

13 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions Inc. announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

2 Aug 2013

Viewpoints: A 'clever' fix for contraception coverage; Sanjay Gupta warns doctors to pay attention to health overhaul

Many nonprofit religious organizations have balked at having to insure their employees' birth control -- because they don't believe in artificial contraception -- under the Affordable Care Act. On Friday, the Obama administration announced a solution to this problem. The new health care law guarantees access to preventive services, and contraception falls, appropriately, into that category (Carla Hill, 6/28).

2 Jul 2013

Theoretical mathematical models offer insights into therapeutic, prevention strategies for HIV

The first few hours to days following exposure to human immunodeficiency virus can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models.

1 Jun 2013

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

UMass Medical, Serum Institute of India partner on anti-rabies monoclonal antibody pivotal trial

A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute of India, Ltd., is starting to enroll patients.

8 Aug 2012

Ethiopia's workplace HIV/AIDS policy aims to help employers, employees nationwide

Ethiopia's new HIV/AIDS workplace policy, instituted in January by the government in cooperation with the country's main employees' and employers' associations, "is expected to protect job seekers from mandatory HIV tests, while facilitating voluntary counseling and testing and defending the right of employees living with HIV to medical leave or job re-allocation," PlusNews reports.

29 Mar 2012

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.

9 Sep 2011

HRSA announces $5.1M in awards as part of Ryan White HIV/AIDS Program

The Health Resources and Services Administration (HRSA) today announced awards of $5.1 million to provide training and technical assistance (TA) as part of the Ryan White HIV/AIDS Program, which provides HIV-related services in the United States for those who do not have sufficient health care coverage or financial resources for coping with HIV disease.

8 Sep 2011

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Today was the last day of the 18th Conference on Retroviruses and Opportunistic Infections, a key HIV/AIDS research meeting being held at the Hynes Convention Center in Boston from February 27 through March 2. Highlighted below are selected presentations from March 2nd on research supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both components of the National Institutes of Health.

5 Mar 2011

New international guidelines launched to protect health workers against HIV, TB

Health workers are at the frontline in providing prevention, treatment and care for people living with HIV and TB throughout the world. They are at risk of occupational exposure to HIV and TB but often themselves lack adequate access to protection and treatment. To address this gap, new international guidelines are being launched today by the International Labour Organization, WHO and the Joint United Nations Programme on HIV/AIDS.

20 Nov 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010